|Mr. Daniel Cohen||Chairman & CEO||40k||N/A||N/A|
|Mr. Keith Li CPA||Chief Financial Officer||91k||N/A||1981|
|Dr. Paul Van Slyke Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Harry Resin||Pres of Super Smart||N/A||N/A||N/A|
Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally-derived approved drugs. It also distributes medical cannabis to pharmacies in Germany and rest of the European Union; and owns and operates in the psychedelic smartshop market. In addition, the company engages in the adult use psychedelic retail business; and researching and reformulating established natural medicines. It has a research agreement with the University of Michigan to evaluate N, N-dimethyltryptamine's (DMT) potential role in normal, diseased, and altered states of consciousness, as well as an agreement with Southwest Research Institute for initiating non-clinical and clinical manufacturing of Cepharanthine. The company was formerly known as Aura Health Inc. and changed its name to Pharmadrug Inc. in October 2019. The company is based in Toronto, Canada.
Pharmadrug Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.